A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01572519 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Hodgkin Lymphoma

Interventions

DRUG: Phase 1, Cohort 1
DRUG: Phase 1, Cohort 2
DRUG: Phase 1, Cohort 3
DRUG: Phase 1, Cohort 4
DRUG: Phase 2

Sponsor

Janssen Research & Development, LLC